Skip to content
EmergingResearch compoundReference only

Adamax

Experimental nootropic: a modified version of the Russian peptide Semax; only early animal data exist, no human studies.

NootropicPeptidePeptideMemoryBDNFBDNF

Pharmacology

ClassPeptide · Memory · BDNF
Primary targetBDNF / TrkB signaling
Targets3 receptor targets
EvidenceReference only
Affected systemsBDNF

Contents

DETAILED OVERVIEW

What is Adamax?

Adamax is a modified version of Semax, a Russian peptide (a short protein chain), to which a fat-soluble adamantyl group has been attached. In Russia the parent compound, Semax, is approved as a medicine, but Adamax has only academic research status; it is not approved in the European Union or the United States either.

The modification is meant to help the compound cross the blood-brain barrier more easily and last longer, because the adamantyl group protects the peptide from enzymes that break it down. Animal studies have described effects that raise the brain's own growth factors (BDNF and NGF) and reduce anxiety. There are no human studies, only user reports and animal data on how the compound behaves in the body, so its effect in people is not proven. Knowledge about side effects comes mainly from Semax and user reports: headache, irritability, sleep problems and irritation of the nasal lining may occur. There are no safety data for pregnancy and breastfeeding.

Mechanism

Melanocortin (MCR3/4) + BDNF/NGF inducer

Half-life

4-6 h (intranasal, animal PK)

Legal status

EU/USA: research compound, not approved

Receptor profile

  • BDNF / TrkBStrong
  • Enkephalin-degrading enzymesModerate
  • Blood-brain barrier penetration (adamantane)Moderate

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Limited human safety data, side-effect profile is mainly preclinical and anecdotal
  • Intranasal use may cause nasal mucosa irritation, stinging and sneezing
  • Headache and transient irritability (anecdotally reported with the parent Semax)
  • Overstimulation, restlessness or sleep disturbance, especially with late-evening dosing
  • Mood swings or anxiety-like sensations in some user reports
  • Unknown long-term safety, chronic effects of the adamantyl modification are unstudied

Contraindications · 5

  • Avoid during pregnancy and breastfeeding, no safety data available
  • Unapproved research compound without human clinical trials, not recommended without medical supervision
  • Caution with anxiety, mood disorders or ongoing psychiatric treatment due to neuroactive effects
  • Avoid combining with other CNS-active agents, stimulants or peptides, interactions are unknown
  • Purity and composition not guaranteed from grey-market sources, risk of contamination

Related Nootropics

Same therapeutic category

FAQ

FAQ

Adamax is a modified version of the Russian peptide Semax, with a fat-soluble group attached to help it cross the blood-brain barrier more easily and act for longer. The idea is that it would give a stronger, longer-lasting boost to the brain's own growth-factor (neurotrophic) signaling, but since this is an experimental/community modification, no concrete human trial data on its effects is given in the source.

Telegram

Have a question about Adamax?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
Formulamixture
UpdatedOctober 14, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.